- Citations, last 5 years
- 399
- Works, last 5 years
- 30
- h-index
- 99
- Scientists listed
- 1
- Grants since 2016
- 7
Grants received
2025–2026 · research · R43
Development of advanced glycation end product (AGE)-breaking enzymes as a novel therapy for the treatment of diabetic retinopathy
Aaron Cravens · Reata Pharmaceuticals (United States) · funded by National Institutes of Health
2024–2025 · research · R43
Development of advanced glycation end product (AGE)-breaking enzymes as a novel therapy for the treatment of diabetic kidney disease
Aaron Cravens · Reata Pharmaceuticals (United States) · funded by National Institutes of Health
2024–2025 · research · R43
An enzyme-based assay for the detection of carboxyethyl lysine-protein adducts
Aaron Cravens · Reata Pharmaceuticals (United States) · funded by National Institutes of Health
2023–2024 · research · R43
Development of enzymatic tools for rapid measurement of Advanced Glycation End Product-protein adducts
Aaron Cravens · Reata Pharmaceuticals (United States) · funded by National Institutes of Health
2023–2024 · research · R43
An enzyme-based assay for the detection of acetaldehyde-protein adducts
Kevin K Desai · Reata Pharmaceuticals (United States) · funded by National Institutes of Health
2023–2027 · research · R44
Development of enzymatic tools for rapid measurement of Advanced Glycation and Lipoxidation End Product-protein adducts
Aaron Cravens · Reata Pharmaceuticals (United States) · funded by National Institutes of Health
2021–2023 · grant · Standard Grant
SBIR Phase I: Automatic Data Series Extraction from a Text Corpus
Chit-Kwan Lin · Reata Pharmaceuticals (United States) · funded by National Science Foundation